Myriad Genetics, Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $210M | ↓-0.4% | — | — | — |
| 2025-09-30 | $206M | ↓-3.6% | $-27M | ↓-24.0% | -11.3% |
| 2025-06-30 | $213M | ↑+0.8% | $-331M | ↓-800.5% | -154.5% |
| 2025-03-31 | $196M | ↓-3.1% | $-100K | ↑+99.6% | -14.8% |
| 2024-12-31 | $211M | ↑+7.1% | — | — | — |
| 2024-09-30 | $213M | ↑+11.2% | $-22M | ↑+63.9% | -9.4% |
| 2024-06-30 | $212M | ↑+15.3% | $-37M | ↑+68.4% | -17.3% |
| 2024-03-31 | $202M | ↑+11.6% | $-26M | ↑+52.5% | -13.8% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 67 quarters
margin trajectory tells the operating-leverage storyGo deeper
MYGN Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyMYGN Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics